SK

PCT09

RAW SEQUENCE LISTING   DATE: 01/22/2002
PATENT APPLICATION: US/09/701,623C   TIME: 10:33:26

Input Set : A:\Mc11.app
Output Set: N:\CRF3\01182002\I701623C.raw

ENTERED

```
 3 <110> APPLICANT: Wang Ph.D., Chang Yi
 5 <120> TITLE OF INVENTION: PEPTIDE COMPOSITION AS IMMUNOGEN FOR THE TREATMENT OF
 6       ALLERGY
 8 <130> FILE REFERENCE: 11514153US1
10 <140> CURRENT APPLICATION NUMBER: 09/701,623C
11 <141> CURRENT FILING DATE: 2000-12-01
13 <150> PRIOR APPLICATION NUMBER: PCT/US99/13959
14 <151> PRIOR FILING DATE: 1999-06-21
16 <150> PRIOR APPLICATION NUMBER: 09/100,287
17 <151> PRIOR FILING DATE: 1998-06-20
19 <160> NUMBER OF SEQ ID NOS: 91
21 <170> SOFTWARE: PatentIn Ver. 2.1
23 <210> SEQ ID NO: 1
24 <211> LENGTH: 325
25 <212> TYPE: PRT
26 <213> ORGANISM: HUMAN
28 <220> FEATURE:
29 <223> OTHER INFORMATION: CH2CH3 of human IgE
31 <300> PUBLICATION INFORMATION:
32 <301> AUTHORs: Dorrington,
33       Bennich,
34 <303> JOURNAL: Immunology
35 <304> VOLUME: 41
36 <306> PAGES: 3-25
37 <307> DATE: 1978
39 <400> SEQUENCE: 1
40 Val Cys Ser Arg Asp Phe Thr Pro Pro Thr Val Lys Ile Leu Gln Ser
41  1               5                  10                  15
43 Ser Cys Asp Gly Gly Gly His Phe Pro Pro Thr Ile Gln Leu Leu Cys
44              20                  25                  30
46 Leu Val Ser Gly Tyr Thr Pro Gly Thr Ile Asn Ile Thr Trp Leu Glu
47          35                  40                  45
49 Asp Gly Gln Val Met Asp Val Asp Leu Ser Thr Ala Ser Thr Thr Gln
50        50                  55                  60
52 Glu Gly Glu Leu Ala Ser Thr Gln Ser Glu Leu Thr Leu Ser Gln Lys
53  65                  70                  75                  80
55 His Trp Leu Ser Asp Arg Thr Tyr Thr Cys Gln Val Thr Tyr Gln Gly
56              85                  90                  95
58 His Thr Phe Glu Asp Ser Thr Lys Lys Cys Ala Asp Ser Asn Pro Arg
59              100                 105                 110
61 Gly Val Ser Ala Tyr Leu Ser Arg Pro Ser Pro Phe Asp Leu Phe Ile
62          115                 120                 125
64 Arg Lys Ser Pro Thr Ile Thr Cys Leu Val Val Asp Leu Ala Pro Ser
```

```
65      130                135                140
67 Lys Gly Thr Val Asn Leu Thr Trp Ser Arg Ala Ser Gly Lys Pro Val
68 145                150                155                160
70 Asn His Ser Thr Arg Lys Glu Glu Lys Gln Arg Asn Gly Thr Leu Thr
71                165                170                175
73 Val Thr Ser Thr Leu Pro Val Gly Thr Arg Asp Trp Ile Glu Gly Glu
74                180                185                190
76 Thr Tyr Gln Cys Arg Val Thr His Pro His Leu Pro Arg Ala Leu Met
77           195                200                205
79 Arg Ser Thr Thr Lys Thr Ser Gly Pro Arg Ala Ala Pro Glu Val Tyr
80      210                215                220
82 Ala Phe Ala Thr Pro Glu Trp Pro Gly Ser Arg Asp Lys Arg Thr Leu
83 225                230                235                240
85 Ala Cys Leu Ile Gln Asn Phe Met Pro Glu Asp Ile Ser Val Gln Trp
86                245                250                255
88 Leu His Asn Glu Val Gln Leu Pro Asp Ala Arg His Ser Thr Thr Gln
89                260                265                270
91 Pro Arg Lys Thr Lys Gly Ser Gly Phe Phe Val Phe Ser Arg Leu Glu
92           275                280                285
94 Val Thr Arg Ala Glu Trp Gln Glu Lys Asp Glu Phe Ile Cys Arg Ala
95      290                295                300
97 Val His Glu Ala Ala Ser Pro Ser Gln Thr Val Gln Arg Ala Val Ser
98 305                310                315                320
100 Val Asn Pro Gly Lys
101                325
```

104 <210> SEQ ID NO: 2
105 <211> LENGTH: 312
106 <212> TYPE: PRT
107 <213> ORGANISM: Dog
109 <220> FEATURE:
110 <223> OTHER INFORMATION: CH2CH3n of dog IgE
112 <300> PUBLICATION INFORMATION:
113 <301> AUTHORs: Patel,
114 <303> JOURNAL: Immunogenetics
115 <304> VOLUME: 41
116 <306> PAGES: 282-286
117 <307> DATE: 1995
119 <400> SEQUENCE: 2

```
120 Ala Cys Ala Leu Asn Phe Ile Pro Pro Thr Val Lys Leu Phe His Ser
121   1           5                10                15
123 Ser Cys Asn Pro Val Gly Asp Thr His Thr Thr Ile Gln Leu Leu Cys
124                20                25                30
126 Leu Ile Ser Gly Tyr Val Pro Gly Asp Met Glu Val Ile Trp Leu Val
127           35                40                45
129 Asp Gly Gln Lys Ala Thr Asn Ile Phe Pro Tyr Thr Ala Pro Gly Thr
130      50                55                60
132 Lys Glu Gly Asn Val Thr Ser Thr His Ser Glu Leu Asn Ile Thr Gln
133   65                70                75                80
135 Gly Glu Trp Val Ser Gln Lys Thr Tyr Thr Cys Gln Gly Phe Thr Phe
```

```
136                85              90              95
138 Lys Asp Glu Ala Arg Lys Cys Ser Glu Ser Asp Pro Arg Gly Val Thr
139            100             105             110
141 Ser Tyr Leu Ser Pro Pro Ser Pro Leu Asp Leu Tyr Val His Lys Ala
142            115             120             125
144 Pro Lys Ile Thr Cys Leu Val Val Asp Leu Ala Thr Met Glu Gly Met
145        130             135             140
147 Asn Leu Thr Trp Tyr Arg Glu Ser Lys Glu Pro Val Asn Pro Gly Pro
148 145             150             155             160
150 Leu Asn Lys Lys Asp His Phe Asn Gly Thr Ile Thr Val Thr Ser Thr
151            165             170             175
153 Leu Pro Val Asn Thr Asn Asp Trp Ile Glu Gly Glu Thr Tyr Tyr Cys
154            180             185             190
156 Arg Val Thr His Pro His Leu Pro Lys Asp Ile Val Arg Ser Ile Ala
157            195             200             205
159 Lys Ala Pro Gly Lys Arg Ala Pro Pro Asp Val Tyr Leu Phe Leu Pro
160        210             215             220
162 Pro Glu Glu Glu Gln Gly Thr Lys Asp Arg Val Thr Leu Thr Cys Leu
163 225             230             235             240
165 Ile Gln Asn Phe Phe Pro Ala Asp Ile Ser Val Gln Trp Leu Arg Asn
166            245             250             255
168 Asp Ser Pro Ile Gln Thr Asp Gln Tyr Thr Thr Thr Gly Pro His Lys
169            260             265             270
171 Val Ser Gly Ser Arg Pro Ala Phe Phe Ile Phe Ser Arg Leu Glu Val
172        275             280             285
174 Ser Arg Val Asp Trp Glu Gln Lys Asn Lys Phe Thr Cys Gln Val Val
175        290             295             300
177 His Glu Ala Leu Ser Gly Ser Arg
178 305             310
181 <210> SEQ ID NO: 3
182 <211> LENGTH: 313
183 <212> TYPE: PRT
184 <213> ORGANISM: RAT
186 <220> FEATURE:
187 <223> OTHER INFORMATION: CH2CH3 of rat IgE
189 <300> PUBLICATION INFORMATION:
190 <301> AUTHORs: Dorrington,
191         Bennich,
192 <303> JOURNAL: Immunology
193 <304> VOLUME: 41
194 <306> PAGES: 3-25
195 <307> DATE: 1978
197 <300> PUBLICATION INFORMATION:
198 <301> AUTHORs: Patel,
199 <303> JOURNAL: Immunogenetics
200 <304> VOLUME: 41
201 <306> PAGES: 282-286
202 <307> DATE: 1995
204 <300> PUBLICATION INFORMATION:
```

```
205 <301> AUTHORs: Steen,
206 <303> JOURNAL: J. Mol. Biol.
207 <304> VOLUME: 177
208 <306> PAGES: 19-32
209 <307> DATE: 1984
211 <300> PUBLICATION INFORMATION:
212 <301> AUTHORs: Ishida,
213 <303> JOURNAL: EMBO J.
214 <304> VOLUME: 1
215 <306> PAGES: 1117-1123
216 <307> DATE: 1982
218 <400> SEQUENCE: 3
219 Ala Arg Pro Val Asn Ile Thr Lys Pro Thr Val Asp Leu Leu His Ser
220   1               5                  10                  15
222 Ser Cys Asp Pro Asn Ala Phe His Ser Thr Ile Gln Leu Tyr Cys Phe
223             20                  25                  30
225 Val Tyr Gly His Ile Gln Asn Asp Val Ser Ile His Trp Leu Met Asp
226         35                  40                  45
228 Asp Arg Lys Ile Tyr Asp Thr His Ala Gln Asn Val Leu Ile Lys Glu
229     50                  55                  60
231 Glu Gly Lys Leu Ala Ser Thr Tyr Ser Arg Leu Asn Ile Thr Gln Gln
232 65                  70                  75                  80
234 Gln Trp Met Ser Glu Ser Thr Phe Thr Cys Lys Val Thr Ser Gln Gly
235                 85                  90                  95
237 Glu Asn Tyr Trp Ala His Thr Arg Arg Cys Ser Asp Asp Glu Pro Arg
238             100                 105                 110
240 Gly Val Ile Thr Tyr Leu Ile Pro Pro Ser Pro Leu Asp Leu Tyr Glu
241         115                 120                 125
243 Asn Gly Thr Pro Lys Leu Thr Cys Leu Val Leu Asp Leu Glu Ser Glu
244     130                 135                 140
246 Glu Asn Ile Thr Val Thr Trp Val Arg Glu Arg Lys Lys Ser Ile Gly
247 145                 150                 155                 160
249 Ser Ala Ser Gln Arg Ser Thr Lys His His Asn Ala Thr Thr Ser Ile
250             165                 170                 175
252 Thr Ser Ile Leu Pro Val Asp Ala Lys Asp Trp Ile Glu Gly Glu Gly
253             180                 185                 190
255 Tyr Gln Cys Arg Val Asp His Pro His Phe Pro Lys Pro Ile Val Arg
256         195                 200                 205
258 Ser Ile Thr Lys Ala Leu Gly Leu Arg Ser Ala Pro Glu Val Tyr Val
259     210                 215                 220
261 Phe Leu Pro Pro Glu Glu Glu Glu Lys Asn Lys Arg Thr Leu Thr Cys
262 225                 230                 235                 240
264 Leu Ile Gln Asn Phe Phe Pro Glu Asp Ile Ser Val Gln Trp Leu Gln
265             245                 250                 255
267 Asp Ser Lys Leu Ile Pro Lys Ser Gln His Ser Thr Thr Thr Pro Leu
268             260                 265                 270
270 Lys Thr Asn Gly Ser Asn Gln Arg Phe Phe Ile Phe Ser Arg Leu Glu
271             275                 280                 285
273 Val Thr Lys Ala Leu Trp Thr Gln Thr Lys Gln Phe Thr Cys Arg Val
```

RAW SEQUENCE LISTING   DATE: 01/22/2002
PATENT APPLICATION: US/09/701,623C   TIME: 10:33:26

Input Set : A:\Mc11.app
Output Set: N:\CRF3\01182002\I701623C.raw

```
274      290           295              300
276 Ile His Glu Ala Leu Arg Glu Pro Arg
277 305              310
280 <210> SEQ ID NO: 4
281 <211> LENGTH: 313
282 <212> TYPE: PRT
283 <213> ORGANISM: MOUSE
285 <220> FEATURE:
286 <223> OTHER INFORMATION: CH2CH3 of mouse IgE
288 <400> SEQUENCE: 4
289 Val Arg Pro Val Thr His Ser Leu Ser Pro Pro Trp Ser Tyr Ser Ile
290   1           5               10                  15
292 His Arg Cys Asp Pro Asn Ala Phe His Ser Thr Ile Gln Leu Tyr Cys
293          20              25                  30
295 Phe Ile Tyr Gly His Ile Leu Asn Asp Val Ser Val Ser Trp Leu Met
296         35              40                  45
298 Asp Asp Arg Glu Ile Thr Asp Thr Leu Ala Gln Thr Val Leu Ile Lys
299     50              55                  60
301 Glu Glu Gly Lys Leu Ala Ser Thr Cys Ser Lys Leu Asn Ile Thr Glu
302   65              70                  75                  80
304 Gln Gln Trp Met Ser Glu Ser Thr Phe Thr Cys Arg Val Thr Ser Gln
305              85                  90                  95
307 Gly Cys Asp Tyr Leu Ala His Thr Arg Arg Cys Pro Asp His Glu Pro
308          100             105                 110
310 Arg Gly Ala Ile Thr Tyr Leu Ile Pro Pro Ser Pro Leu Asp Leu Tyr
311          115             120                 125
313 Gln Asn Gly Ala Pro Lys Leu Thr Cys Leu Val Val Asp Leu Glu Ser
314      130             135                 140
316 Glu Lys Asn Val Asn Val Thr Trp Asn Gln Glu Lys Lys Thr Ser Val
317 145             150                 155                 160
319 Ser Ala Ser Gln Trp Tyr Thr Lys His His Asn Asn Ala Thr Thr Ser
320              165             170                 175
322 Ile Thr Ser Ile Leu Pro Val Val Ala Lys Asp Trp Ile Glu Gly Tyr
323          180             185                 190
325 Gly Tyr Gln Cys Ile Val Asp Arg Pro Asp Phe Pro Lys Pro Ile Val
326          195             200                 205
328 Arg Ser Ile Thr Lys Thr Pro Gly Gln Arg Ser Ala Pro Glu Val Tyr
329      210             215                 220
331 Val Phe Pro Pro Pro Glu Glu Glu Ser Glu Asp Lys Arg Thr Leu Thr
332 225             230                 235                 240
334 Cys Leu Ile Gln Asn Phe Phe Pro Glu Asp Ile Ser Val Gln Trp Leu
335              245             250                 255
337 Gly Asp Gly Lys Leu Ile Ser Asn Ser Gln His Ser Thr Thr Thr Pro
338          260             265                 270
340 Leu Lys Ser Asn Gly Asn Gln Gly Phe Phe Ile Phe Ser Arg Leu Glu
341          275             280                 285
343 Val Ala Lys Thr Leu Trp Thr Gln Arg Lys Gln Phe Thr Cys Gln Val
344      290             295                 300
346 Ile His Glu Ala Leu Gln Lys Pro Arg
```

Use of n and/or Xaa has been detected in the Sequence Listing.
Review the Sequence Listing to insure a corresponding
explanation is presented in the <220> to <223> fields of
each sequence using n or Xaa.

VERIFICATION SUMMARY   DATE: 01/22/2002
PATENT APPLICATION: **US/09/701,623C**   TIME: 10:33:27

Input Set : **A:\Mc11.app**
Output Set: **N:\CRF3\01182002\I701623C.raw**

```
L:488  M:341 W: (46) "n" or "Xaa" used, for SEQ ID#:10
L:546  M:341 W: (46) "n" or "Xaa" used, for SEQ ID#:11
L:549  M:341 W: (46) "n" or "Xaa" used, for SEQ ID#:11
L:639  M:341 W: (46) "n" or "Xaa" used, for SEQ ID#:16
L:704  M:341 W: (46) "n" or "Xaa" used, for SEQ ID#:18
L:756  M:341 W: (46) "n" or "Xaa" used, for SEQ ID#:19
L:759  M:341 W: (46) "n" or "Xaa" used, for SEQ ID#:19
L:808  M:341 W: (46) "n" or "Xaa" used, for SEQ ID#:20
L:872  M:341 W: (46) "n" or "Xaa" used, for SEQ ID#:21
L:939  M:341 W: (46) "n" or "Xaa" used, for SEQ ID#:22
L:942  M:341 W: (46) "n" or "Xaa" used, for SEQ ID#:22
L:1003 M:341 W: (46) "n" or "Xaa" used, for SEQ ID#:23
L:1006 M:341 W: (46) "n" or "Xaa" used, for SEQ ID#:23
L:1055 M:341 W: (46) "n" or "Xaa" used, for SEQ ID#:24
L:1167 M:341 W: (46) "n" or "Xaa" used, for SEQ ID#:27
L:1170 M:341 W: (46) "n" or "Xaa" used, for SEQ ID#:27
L:1779 M:341 W: (46) "n" or "Xaa" used, for SEQ ID#:60
L:2203 M:341 W: (46) "n" or "Xaa" used, for SEQ ID#:85
```